Evidence map›Paper›PMID 34018720›Full record

ArticleACS biomaterials science & engineering2021

Changing the Wound: Covalent Immobilization of the Epidermal Growth Factor.

VijayKrishna Raghunathan, Shin Ae Park, Nihar M Shah, Christopher M Reilly, Leandro Teixeira, Richard Dubielzig, Yow-Ren Chang, Monica J Motta, Michael J Schurr, Jonathan F McAnulty and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS biomaterials science & engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. A Review of Genes Involved in Wound Healing.Medical journal of the Islamic Republic of Iran · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

VijayKrishna RaghunathanDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.ORCID 0000-0003-1702-591X
Shin Ae ParkDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.
Nihar M ShahDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.
Christopher M ReillyDepartment of Pathology, Microbiology & Immunology, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.
Leandro TeixeiraDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.ORCID 0000-0001-9960-678X
Richard DubielzigDepartment of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Yow-Ren ChangDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.ORCID 0000-0003-2770-8693
Monica J MottaDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.
Michael J SchurrDivison of General Surgery, Mountain Area Health Education Center, 509 Biltmore Avenue, Asheville, North Carolina 28803, United States.
Jonathan F McAnultyDepartment of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive, Madison, Wisconsin 53706, United States.
R Rivkah IsseroffDepartment of Dermatology, UC Davis School of Medicine, University of California Davis, Sacramento, California 95817, United States.ORCID 0000-0001-7813-0858
Nicholas L AbbottSmith School of Chemical and Biomolecular Engineering, Cornell University, 1 Hoy Plaza, Ithaca, New York 14853 United States.ORCID 0000-0002-9653-0326
Christopher J MurphyDepartment of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, One Shields Avenue, Davis, California 95616, United States.
University of California, Davis · USUniversity of Wisconsin–Madison · USCornell University · USMedtronic (United States) · USMountain Area Health Education Center · USPurdue University West Lafayette · USUniversity of Houston · US

Funding

VISION RESEARCH CORE GRANTP30EY012576 · NEI · UNIVERSITY OF CALIFORNIA DAVIS · PI MARIE E BURNS · 1999 to 2026
$18.9M
Beyond Biomaterials: Engineering the Wound BedRC2AR058971 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ABBOTT, NICHOLAS L, MURPHY, CHRISTOPHER JOHN · 2009 to 2010
$4.0M
Biomechanical and genetic effects on glaucoma progressionK08EY030950 · NEI · PURDUE UNIVERSITY · PI PARK, SHIN AE · 2020 to 2024
$823k
NEI NIH HHS K08 EY030950NEI NIH HHS P30 EY012576NIAMS NIH HHS RC2 AR058971
6 · The paper itself

Abstract

Re-epithelialization of wounds is a critical element of wound closure. Growth factors have been used in combination with conventional wound management to promote closure, but the method of delivery has been limited to the topical application of ointment formulations. Cytoactive factors delivered in this way have short resident times in wounds and have met with limited success. Here, we demonstrate that methods used to covalently immobilize proteins on synthetic materials can be extended to immobilize cytoactive factors such as the epidermal growth factor (EGF) onto the wound beds of genetically diabetic mice that exhibit impaired healing. Full-thickness splinted excisional wounds were created in diabetic (db/db) mice with a well-defined silicone splint to limit wound contracture. Wound surfaces were treated with a reducing agent to expose sulfhydryl groups and subsequently treated with EGF modified with a heterobifunctional crosslinker. This allowed for the covalent immobilization of the EGF to the wound surface. The conjugation chemistry was validated in vitro and in vivo. In a separate group of mice, wounds were topically treated twice daily with soluble EGF. The mice were evaluated over 11 days for wound closure. This covalent immobilization strategy resulted in EGF being retained on the wound surface for 2 days and significantly increased epithelial wound closure by 20% compared to wounds treated with topical EGF or topical vehicle. Covalent immobilization was not only therapeutically effective but also delivered a markedly reduced load of growth factor to the wound surface compared to topical application (when only 180 ng of EGF was immobilized onto the wound surface in comparison with 7200 ng of topically applied EGF over a period of 11 days). No adverse effects were observed in treated wounds. Results obtained provide proof of concept for the effectiveness of covalent immobilization in the treatment of dysregulated wounds. The covalent immobilization of cytoactive factors represents a potentially transformative approach to the management of difficult chronic wounds.

Indexed as

Diabetes Mellitus, ExperimentalEpidermal Growth FactorAnimalsMiceRe-EpithelializationWound HealingEpidermal Growth Factorbioconjugationcovalent immobilizationdiabetesepidermal growth factorwound healing

Identifiers

PMID34018720
PMCPMC8207651
OpenAlexW3160268261

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.